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ABREVIATIONS 
 
 
ACE   affinity capillary electrophoresis 
AED   antiepileptic drugs 
AGP    alpha-1-acid glycoprotein 
AMPA   alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BMC   biopartitioning micellar chromatography 
CE   capillary electrophoresis 
CNS   central nervous system 
CZE   capillary zonal electrophoresis 
D   ligand such as drug 
DAD   diode array detection 
EOF   electroosmotic flow 
FA   frontal analysis capillary electrophoresis 
FACCE  frontal analysis electrophoresis capillary continual 
GABA   gamma-amino butyric acid 
HPLC   high-performance liquid chromatography 
HSA   human serum albumin 
HD   Hummel-Dreyer capillary electrophoresis 
ID   internal diameter 
P   receptor such as protein 
UV   ultraviolet 
VACE   vacancy affinity capillary electrophoresis  
VP   vacancy peak capillary electrophoresis 
WHO   World health organization 
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1. INTRODUCTION 
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Drug action in living organisms is the result of a large number of pharmacological 
processes. In this sense, the interactions between drugs and biomembranes, plasma 
proteins, enzymes or receptors are decisive features of the final biological activity of drugs 
[1].  
Plasma protein binding has a significant effect on the pharmacokinetic and 
pharmacodynamic properties of drugs. Pharmacokinetic studies are related to the drug 
absorption, distribution, metabolism and excretion, and plasma drug concentrations over 
time; pharmacodynamic studies are concerned with the relationships between drug effect 
and drug concentration at the site of action. At pharmacodynamic level, drug–plasmatic 
protein complexes serve as drug reservoirs to supply free drug, as the net drug 
concentration is diminished in the body by various elimination processes. So, drug–
plasmatic protein binding can prolong the duration of drug action [2]. Thus, an important 
topic in the drug discovery and development of drugs is the role of drug binding to serum 
proteins [1].  
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 THE AIM 
 
The aim of the diploma thesis is to study the applicability of CE-FA procedure for the 
characterization of the interaction between barbiturates and benzodiazepines and HSA and 
AGP under physiological conditions.  
Furthermore, to evaluate the binding of these drugs to all plasmatic proteins using 
ultrafiltration and capillary electrophoresis. 
Finally, to outline the effect of some physicochemical properties of the compounds studied 
(acid–base ionization constants, octanol–water partition coefficients and retention data in 
biopartitioning micellar chromatography) and some structural properties (molar volume, 
molecular weight) on the affinity of drugs towards plasmatic proteins. The results obtained 
to compare and to discuss. 
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2. THEORETICAL PART 
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2.1 PLASMATIC PROTEINS 
 
Human plasma contains over 60 proteins, human serum albumin,  α1-acid glycoprotein, 
lipoproteins and globulins being the most important drug binding proteins [3]. 
 
2.1.1 Human serum albumin 
 
HSA is the most abundant plasma protein which accounts for approximately 60% of the 
total protein corresponding to a concentration of around 0.6mM [4]. HSA contains 585 
amino acids and has a molecular mass of 66 500 Da [1]. 
 
2.1.2 Alpha-1-acid glycoprotein 
 
Concentration of AGP can vary considerably in several physiological and pathological 
conditions; in healthy subjects it ranges from 10 to 30μM. Since AGP is an acute phase 
protein, several inflammatory states (infections, rheumatic disorders, and surgical injury) 
and pathological conditions (e.g. myocardial infarction, malignancies, and nephritis) 
elevate its serum concentration up to three- or four-fold [3]. 
 
2.1.3 Drug binding sites 
 
While drug binding to plasma was first considered to represent a rather unspecific 
physicochemical phenomenon, similar to the adsorption of small molecules to charcoal or 
similar compounds, accumulated evidence indicates that drug binding to albumin and to 
AGP at low molar drug/protein ratios occurs at only a very few ligand binding sites of both 
proteins, respectively [5]. Therefore, a knowledge of the properties of these drug binding 
sites has become an important issue for understanding pharmacokinetically relevant 
binding phenomena such as displacement reactions between different drugs and the 
dramatically altered plasma protein binding of some drugs during several disease states as 
well [6]. 
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2.1.3.1 Drug binding sites of human serum albumin 
 
According to an X-ray crystallographic analysis of HSA and its recombinant version 
(rHSA), the polypeptide chain forms a heart-shaped conformation with the approximate 
dimension of 80× 80×80×30 Å and about 67 % of it consists of α-helices, but no β-sheet is 
evident (Fig. 1).  
 
 
Figure 1: X –ray structure of human serum albumin [4].  
 
X-ray diffraction has also shown that the protein has three homologous domains (I-III), 
each of which is comprised of two subdomains (A and B) [1]. 
HSA interacts reversibly with a broad spectrum of therapeutic agents. Typically, drugs 
bind to one or a very few high-affinity sites with typical association constants in the range 
of 10
4
–10
6
 M
-1
. The pioneering work of Sudlow et al. [7] based on the displacement of 
fluorescent probes, revealed that most drugs bind with a high affinity to one of  two sites, 
referred to as site I and site II.  
Typical site I ligands appear to be dicarboxylic acids and/or bulky heterocyclic molecules 
with a negative charge localized in the middle of the molecule. Site I probes include 
warfarin, 5-dimethylaminonaphthalene-1-sulfonamide, dansylamide, dansyl-L-glutamine, 
dansyl-L-asparagine, dansyl-L-lysine and n-butyl-p-aminobenzoate.  
Site I appears to be capacious and flexible and to contain a large number of individual 
ligand-binding sites that sometimes are independent of each other but in other cases, 
mutually influence one another [8].  
 The fact that ligands with very different chemical structures bind to the region with high 
affinity indicates that the site is adaptable. Mutual interactions between bound ligands have 
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been observed and this can be attributed to partially overlapping binding sites, or 
conformational changes in the albumin molecule (allosteric effect or anti-cooperativity). 
Single residue mutations in this region of albumin have a significant effect on the 
conformational and thermal stability of the protein, much more than mutations in site II 
[9].  
Site I is formed as a pocket in subdomain IIA and involves the lone tryptophan of the 
protein (Trp214) [10]. The inside wall of the pocket is formed by hydrophobic side chains, 
whereas the entrance to the pocket is surrounded by positively charged residues. Both 
residues contribute positively (e.g., Trp214 and Arg218) and residues that contribute 
negatively (e.g., Lys199 and His242) to the binding have been identified in the high 
affinity binding of ligands such as warfarin.  
 
Ligands that bind to site II (also called the indolebenzodiazepine site) are often aromatic 
carboxylic acids with a negatively charged acidic group at one end of the molecule that is 
separate from a hydrophobic center. Dansylsarcosine, dansyl-L-proline, dansylglycine, and 
7-alkylaminocoumarin-4-acetic acids all function as site II probes. Site II seems to be 
smaller, or narrower, than site I, because no large ligands apparently bind to it. It also 
appears to be less flexible, because binding often is strongly affected by stereo selectivity. 
Furthermore, the substitution of ligands with a relatively small group strongly influences 
the binding. Site II is a pocket that is formed in subdomain IIIA principally the same way 
as site I. Among the individual amino acid residue of this subdomain, Arg410 and Tyr411 
are usually assumed to be important [11].  
 
2.1.3.2 Drug binding sites of alpha-1-acid glycoprotein 
 
The single polypeptide chain of serum AGP (183 residues, average Mw ≈ 41,000) is 
heavily glycosilated, the carbohydrate content is 41–45%. Acidity of the protein 
(isoelectric point = 2.7) is due to the presence of sialic acid residues.  
Genetic polymorphism of AGP has been long known, it has three major variants (F1, S, 
and A) which differ from one another in their primary structure. The difference between F1 
and S arises from a substitution of one amino acid, while the A variant differs from F1/S 
by 22 residues [12]. The relative abundance in commercial, pooled-source protein of the 
F1, S and A variants has been reported to be ≈40, ≈30, and ≈30%, respectively [13]. There 
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is a large difference in the binding of certain drugs to the F1/S and A variants of AGP [13-
15].  
Although AGP is among the best-studied plasma proteins, its three-dimensional structure 
and physiological function are still unresolved. AGP is an all-β protein with high β-sheet 
content (≈40%) and as the member of the lipocalin family its overall fold consists of eight 
antiparallel β-strands which form the so called β-barrel with a central hydrophobic pocket 
[16-18]. In relation to the large number of papers reporting AGP binding parameters of 
various drugs, much less attention has been paid on the identification of the ligand binding 
site(s) and binding mechanism though the detailed characterization of the binding sites of 
AGP is far from complete [4]. 
Some inconsistent findings indicate that AGP contains a wide drug-binding region for 
basic, acidic and neutral drugs (Fig. 2). Thus, more attention should be paid to the 
characterization  of drug binding sites on AGP [19].  
 
 
 
Figure 2: Structure of human alpha-1-acid glycoprotein [4]. 
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2.2 OBSERVED DRUGS 
 
2.2.1 Barbiturates 
 
2.2.1.1 Mechanism of action 
The principal mechanism of action of barbiturates is their affinity for the GABAA receptor. 
GABA is the principal inhibitory neurotransmitter in the central nervous system. 
Barbiturates bind to the GABAA receptor at the alpha subunit, which are binding sites 
distinct from GABA itself and also distinct from the benzodiazepine binding site. Like 
benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. In addition to 
this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of 
glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the 
mammalian CNS. Taken together, the findings that barbiturates potentiate inhibitory 
GABAA receptors and inhibit excitatory AMPA receptors can explain the CNS-depressant 
effects of these agents. At higher concentration they inhibit the Ca
2+
 dependent release of 
neurotransmitters [20]. 
2.2.1.2 Therapeutic use 
Barbiturates have been long used as anxiolytics and hypnotics. Today benzodiazepines 
have largely supplanted them for these purposes, because benzodiazepines have less 
potential for abuse and less danger of lethal overdose [21].  
Phenobarbital is the most widely used anticonvulsant worldwide and the oldest still in use. 
It also has sedative and hypnotic properties but, as with other barbiturates, has been 
superseded by the benzodiazepines for these indications. The World Health Organization 
recommends its use as first-line for partial and generalized tonic-clonic seizures (those 
formerly known as Grand Mal) in developing countries. It is a core medicine in the WHO 
Model List of Essential Medicines, which is a list of minimum medical needs for a basic 
health care system [22]. In more affluent countries it is no longer recommended as a first-
line medication, however it is relied on as an alternate when a patient fails to respond to 
treatment with more modern AED's [23]. It is still commonly used around the world to 
treat neonatal seizures [24].  
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Mephobarbital is used as a sedative, anxiolytic and anticonvulsant. It is the N-methylated 
analogue of phenobarbital, and has similar indications, therapeutic value, and tolerability 
[21]. 
Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was also 
marketed as a rapid-acting sleeping medication with short duration and is still used in some 
scientific research [21]. 
Butobarbital is a drug which is a barbiturate derivative. It is prescribed for severe insomnia 
[21]. 
2.2.1.3 Dependence, tolerance and overdose 
Barbiturate use can lead to both psychological and physical dependence. Psychological 
addiction can occur quickly. Signs of drug dependence include relying on a drug regularly 
for a desired effect. The addicted abuser believes he or she must take a barbiturate to sleep, 
relax, or just get through the day. Continued use of barbiturates leads to physical 
dependence. 
As people develop a tolerance for barbiturates, they may need more of the drug or a higher 
dosage to get the desired effect. This can lead to an overdose, which results when a person 
takes a larger-than-prescribed dose of a drug. 
The amount of a fatal dosage of barbiturate varies from one individual to another. 
However, the lethal dose is usually ten to fifteen times as large as a usual dose. An 
overdose affects the heart and the respiratory system. Symptoms of overdose of 
barbiturates include confusion, decrease in or loss of reflexes, somnolence, pyrexia, 
irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, 
slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the 
eyes, weakness. The user then falls into a coma and dies [21]. 
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2.2.2 Benzodiazepines  
Benzodiazepines gained popularity among medical professionals as an improvement upon 
barbiturates, which have a comparatively narrow therapeutic index, and are far more 
sedating at therapeutic doses. The benzodiazepines are also far less dangerous; death rarely 
results from benzodiazepines overdose, except in cases where it is consumed with large 
amounts of other depressants (such as alcohol or other sedatives) [25].
 
2.2.2.1 Mechanism of action  
Benzodiazepines bind to a specific subunit on the GABAA receptor at a site that is distinct 
from the binding site of the endogenous GABA molecule [26-30]. The GABAA receptor is 
an inhibitory channel which, when activated, decreases neurologic activity. Because of the 
role of benzodiazepines as a positive allosteric modulators of GABA, when it binds to 
benzodiazepine receptors it causes inhibitory effects. This arises from the 
hyperpolarization of the post-synaptic membrane owing to the control exerted over 
negative chloride ions by GABAA receptors [26, 31]. 
Benzodiazepines have also calcium antagonist activity which may explain reports of 
systemic and coronary vasodilatation by benzodiazepine drugs such as diazepam. 
Benzodiazepines act via micromolar benzodiazepine binding sites as Ca
2+
 channel blockers 
and significantly inhibit depolarization-sensitive calcium uptake [32]. 
Benzodiazepines may influence neurosteroid metabolism and progesterone levels which in 
turn may adversely influence the functions of the brain and reproductive system. The 
pharmacological actions of benzodiazepines at the GABAA receptor are similar to those of 
neurosteroids. Neuroactive steroids are positive allosteric modulators of the GABAA 
receptor, enhancing GABA function. Many benzodiazepines potently inhibit the enzymes 
involved in the metabolism of neurosteroids. Long-term administration of benzodiazepines 
may influence the concentrations of endogenous neurosteroids, and thereby would 
modulate the emotional state. Factors which affect benzodiazepines ability to alter 
neurosteroid levels depend on the molecular make up of the individual benzodiazepine 
molecule. Presence of a substituent at N1 position of the diazepine ring and/or the chloro 
or nitro group at position 7 of the benzene ring contribute to potent inhibition of the 
isoenzymes, and in turn a bromo group at position 7 (for bromazepam) and additional 
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substituents (3-hydroxy group for oxazepam and tetrahydroxazole ring for cloxazolam and 
oxazolam) decrease the inhibitory potency of benzodiazepines on neurosteroids [33].  
Diazepam an chlordiazepoxide inhibit acetylcholine release and sodium-dependent high 
affinity choline uptake which may play a role in diazepam's anticonvulsant properties [34]. 
Diazepam is metabolized via oxidative pathways in the liver via the cytochrome P450 
enzyme system. It has a biphasic half-life of 1–2 and 2–5 days, and has several 
pharmacologically active metabolites [35]. 
Oxazepam is an active metabolite formed during the breakdown of diazepam [36]. 
Oxazepam may be safer than many other benzodiazepines in patients with impaired liver 
function because it does not require hepatic oxidation, but rather it is simply metabolized 
via glucuronidation. This means that oxazepam is less likely to accumulate and cause 
adverse reactions in the elderly or people with liver disease. The half life of oxazepam is 4-
15 hours [29]. 
2.2.2.2 Therapeutic use 
Diazepam, chlordiazepoxide and oxazepam is mainly used to treat anxiety, insomnia, and 
symptoms of acute alcohol or opiate withdrawal [37, 38]. Diazepam has a broad spectrum 
of indications including: treatment of anxiety, panic attacks, and states of agitation, as a 
premedication for inducing sedation, anxiolysis or amnesia before certain medical 
procedures (e.g. endoscopy), treatment of status epilepticus, adjunctive treatment of other 
forms of epilepsy, treatment of the symptoms of alcohol and opiate withdrawal, short-term 
treatment of insomnia [38], adjunctive treatment of painful muscle conditions [39], 
adjunctive treatment of spastic muscular paresis (para-/tetraplegia) caused by cerebral or 
spinal cord conditions such as stroke, multiple sclerosis, spinal cord injury (long-term 
treatment is coupled with other rehabilitative measures) [39].  
Oxazepam is an intermediate acting benzodiazepine with a slow onset of action, so it is 
usually prescribed to individuals who have trouble staying asleep, rather than falling 
asleep. It is commonly prescribed for anxiety disorders with associated tension, irritability, 
and agitation. It is also prescribed for drug and alcohol withdrawal, and for anxiety 
associated with depression. Also prescribed for sleepwalking before a neurologist is 
involved when the sleepwalker may be a problem or danger to themselves [40]. 
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2.2.2.3 Dependence, tolerance and overdose 
Benzodiazepines can cause physical dependence, addiction and what is known as the 
benzodiazepine withdrawal syndrome. Withdrawal from chlordiazepoxide or other 
benzodiazepines often leads to withdrawal symptoms which are similar to those seen with 
alcohol and barbiturates. The higher the dose and the longer the drug is taken the greater 
the risk of experiencing unpleasant withdrawal symptoms. Withdrawal symptoms can 
however occur at standard dosages and also after short term use. Benzodiazepine treatment 
should be discontinued as soon as possible via a slow and gradual dose reduction regime 
[41].  
Chronic use of benzodiazepines lead to the development of tolerance with a decrease in 
number of benzodiazepine binding sites [40, 42]. 
Benzodiazepines are drugs which are very frequently involved in drug intoxication, 
including overdose [43]. Benzodiazepines overdoses are considered a medical emergency 
and generally require the immediate attention of medical personnel. The antidote for an 
overdose of benzodiazepines are flumazenil [21]. An individual who has consumed excess 
benzodiazepines may display some of the following symptoms: Somnolence (difficulty 
staying awake), mental confusion, hypotension, hypoventilation, impaired motor functions 
- impaired reflexes, impaired coordination, impaired balance, dizziness, muscle weakness, 
coma [40]. 
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2.3 ELECTROPHORESIS 
 
2.3.1 General aspects of electrophoresis 
 
The process of electrophoresis is defined as ‘the differential movement or migration of 
ions by attraction or repulsion in an electric field’. In practical terms, a positive (anode) 
and negative (cathode) electrode are placed in a solution containing ions. Then, when a 
voltage is applied across the electrodes, solute ions of different charge, i.e., anions 
(negative) and cations (positive), will move through the solution towards the electrode of 
opposite charge. Capillary electrophoresis, then, is the technique of performing 
electrophoresis in buffer-filled, narrow-bore capillaries, normally from 25 to 100 µm in 
internal diameter. 
 
2.3.2 Instrumentation  
 
The instrumentation required for CE is remarkably simple in design, as fig. 3 illustrates. 
 
 
Figure 3: A schematic representation of the arrangement of the main components of a typical CE instrument 
[44]. 
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The ends of a capillary are placed in separate buffer reservoirs, each containing an 
electrode connected to a high-voltage power supply capable of delivering up to 30 kV. The 
sample is injected onto the capillary by temporarily replacing one of the buffer reservoirs 
(normally at the anode) with a sample reservoir and applying either an electric potential or 
external pressure for a few seconds. After replacing the buffer reservoir, an electric 
potential is applied across the capillary and the separation is performed. Detection of 
separated analytes is achieved directly through the capillary wall near the opposite end 
(normally near the cathode). 
Basic features of a CE instrument include an autosampler, a detection module, a high-
voltage power supply, the capillary and, of course, a computer to control everything [44]. 
Sample injection 
One of the main advantages of CE is its ability to inject extremely small volumes of 
sample. Typical injection volumes range from picoliters to nanoliters. There are two 
commonly used injection methods for CE: hydrodynamic and electrokinetic. 
Hydrodynamic injection is accomplished by the application of a pressure difference 
between the two ends of a capillary. Electrokinetic injection is performed by simply 
turning on the voltage for a certain period of time.  
Capillary column 
The capillary column is a key element of the CE separation. Fused silica is by far the most 
frequently used material, although columns have been made of teflon and borosilicate 
glass. The widespread use of fused silica is due to its intrinsic properties, which include 
transparency over a wide range of the electromagnetic spectrum and a high thermal 
conductance. Fused silica is also easy to manufacture into capillaries with diameters of a 
few micrometers. Many reports describe the covalent attachment of silanes with neutral or 
hydrophilic substituents to the inner wall of the capillary in order to reduce electroosmotic 
flow and prevent adsorption of the analyte. Coatings tend to stabilize the pH.  
An uncoated fused silica capillary is prepared for its first use in electrophoresis by rinsing 
it with 10 to 15 column volumes of 0.1M NaOH followed by 10 to 15 column volumes of 
water and 5 to 10 column volumes of the separation buffer. For a coated capillary, the 
preparation procedure is the same except that 0.1M NaOH is replaced with methanol. In 
commercial instruments, the carrier fluid is forced through the capillary by either applying 
pressure to the inlet reservoir or reducing pressure at the outlet reservoir. 
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Detection modes 
With some modifications, most HPLC detection modes can be applied to CE.  
Table contains a list of commonly used CE detectors and their representative limits of 
detection (LODs) [45]. 
 
Table 1: CE detection modes and representative limits of detection. 
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2.3.3 Electrophoresis theory 
 
The theory that governs electrophoresis is directly applicable to CE and can be dealt with 
very briefly, with reference to a few equations. As mentioned earlier, electrophoresis is the 
movement or migration of ions or solutes under the influence of an electric field. 
Therefore, separation by electrophoresis relies on differences in the speed of migration 
(migration velocity) of ions or solutes. Now, ion migration velocity can be expressed as: 
 
                                                                υ = µe E                                                         (eq.1)                                     
 
where υ is ion migration velocity (m s
-1
), µe is electrophoretic mobility (m
2
 V
-1
 s
-1
) and E is 
electric field strength (Vm
-1
). 
The electric field strength is a function of the applied voltage divided by the total capillary 
length.  
Electrophoretic mobility is a factor that indicates how fast a given ion or solute may move 
through a given medium (such as a buffer solution). It is an expression of the balance of 
forces acting on each individual ion; the electrical force acts in favor of motion and the 
frictional force acts against motion. Since these forces are in a steady state during 
electrophoresis, electrophoretic mobility is a constant (for a given ion under a given set of 
conditions).  
The equation describing electrophoretic mobility is: 
                                                                  µe =
r
q
6
                                                    (eq.2) 
 
where q is the charge on the ion, η is the solution viscosity and r is the ion radius. The 
charge on the ion (q) is fixed for fully dissociated ions, such as strong acids or small ions, 
but can be affected by pH changes in the case of weak acids or bases. The ion radius (r) 
can be affected by the counter-ion present or by any complexing agents used. From (eq.2) 
we can see that differences in electrophoretic mobility will be caused by differences in the 
charge-to-size ratio of analyte ions. Higher charge and smaller size confer greater mobility, 
whereas lower charge and larger size confer lower mobility. 
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Electrophoretic mobility is probably the most important concept to understand in 
electrophoresis. This is because electrophoretic mobility is a characteristic property for any 
given ion or solute and will always be a constant. What is more, it is the defining factor 
that decides migration velocities. This is important, because different ions and solutes have 
different electrophoretic mobilities, so they also have different migration velocities at the 
same electric field strength. It follows that, because of differences in electrophoretic 
mobility, it is possible to separate mixtures of different ions and solutes by using 
electrophoresis. 
 
2.3.4 Electroosmotic flow  
 
A vitally important feature of CE is the bulk flow of liquid through the capillary. This is 
called the electroosmotic flow and is caused as follows. An uncoated fused-silica capillary 
tube is typically used for CE. The surface of the inside of the tube has ionisable silanol 
groups, which are in contact with the buffer during CE. These silanol groups readily 
dissociate, giving the capillary wall a negative charge. Therefore, when the capillary is 
filled with buffer, the negatively charged capillary wall attracts positively charged ions 
from the buffer solution, creating an electrical double layer and a potential difference (zeta 
potential) close to the capillary wall, as described according to Stern’s model. Stern’s 
model for an electrical double layer includes a rigid layer of adsorbed ions and a diffuse 
layer, in which ion diffusion may occur by thermal motion. The zeta potential is the 
potential at any given point in the double layer and decreases exponentially with increasing 
distance from the capillary wall surface. When a voltage is applied across the capillary, 
cations in the diffuse layer are free to migrate towards the cathode, carrying the bulk 
solution with them. The result is a net flow in the direction of the cathode, with a velocity 
described by: 
 
                                                                   υEOF = 







4
E                                            (eq.3)                                                                    
 
where ε is the dielectric constant of a vacuum, ε is the dielectric constant of the buffer, ζ is 
the zeta potential, η is the viscosity of the buffer and E is the applied electric field. The 
terms enclosed in brackets equate to the mobility of the EOF (µEOF). The relationship 
between EOF mobility and EOF velocity is analogous to that between electrophoretic 
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mobility and migration velocity. Indeed, the units for EOF mobility are the same as those 
for electrophoretic mobility. 
 
2.3.4.1 Factors affecting EOF mobility 
 
The main variables affecting EOF mobility are the dielectric constant and viscosity of the 
buffer and the size of the zeta potential.  
The use of buffer additives and/or other modifications of the buffer composition may 
influence the dielectric constant and viscosity of the buffer. Buffer viscosity will also 
depend on the temperature at which the CE separation is performed. 
Zeta Potential 
The zeta potential is proportional to the charge density on the capillary wall, which itself is 
pH dependent. Therefore, EOF mobility will vary according to the buffer pH, such that at 
high pH the EOF mobility will be significantly greater than at low pH. Figure depicts the 
variation of EOF mobility with pH for a typical fused-silica capillary. 
 
 
 
 
Figure 4:  The variation of EOF mobility with changing pH for a typical uncoated fused-silica capillary 
(simulated data)[44]. 
 
Above pH 9, silanols are completely ionized and the EOF mobility is at its greatest. Below 
pH 4, the ionization of silanols is low and the EOF mobility is insignificant. The zeta 
potential will also depend upon the ionic strength of the buffer, because as ionic strength 
increases, the double layer will become compressed, which results in a decreased zeta 
potential and reduced EOF mobility. At pH ~7, the EOF mobility is sufficient to ensure the 
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net migration of most ions towards the cathode, regardless of their charge. Therefore, the 
observed migration velocity of a solute may not be directly related to its electrophoretic 
mobility. Instead, it is related to a combination of both its electrophoretic mobility and the 
EOF mobility. Therefore, a solute’s apparent electrophoretic mobility (µa), which is 
calculated from its observed migration velocity, is the vector sum of its real (or effective) 
electrophoretic mobility (µe) and the EOF mobility (µEOF).  
 
                                                                    µa = µe + µEOF                                                                     (eq.4) 
 
Since samples are normally introduced at the anode and EOF moves from the anode to the 
cathode, cations have positive µe, neutrals have zero µe and anions have negative µe. In 
other words, cations migrate faster than the EOF and anions migrate more slowly than the 
EOF. Neutrals migrate with the same velocity as the EOF. 
 
2.3.4.2 Flow Profile in CE 
 
A further key feature of EOF is that it has flat flow profile, which is shown in figure, 
alongside the parabolic flow profile generated by an external pump, as used for HPLC. 
EOF has a flat profile because its driving force (i.e. charge on the capillary wall) is 
uniformly distributed along the capillary, which means that no pressure drops are 
encountered and the flow velocity is uniform across the capillary. This contrasts with 
pressure-driven flow, yielding a parabolic or laminar flow profile. The flat profile of EOF 
is important because it minimizes zone broadening, leading to high separation efficiencies 
that allow separations on the basis of mobility differences as small as 0.05% [44]. 
 
 
 
Figure 5: Flow profiles of EOF and laminar flow [44]. 
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2.3.5 Capillary electrophoresis in the study of molecular interaction 
 
CE is a well-developed technique for the study of molecular interactions. The method can 
be applied over a very wide pH range (pH 1–14), and be operated with aqueous media. 
Therefore, CE is suited to study almost any biomolecular interaction system.  
The major drawback is still the low capacity of standard CE systems, equipped with UV 
detectors to yield specific information about sample components. CE coupled with other 
detectors, such as CE-mass spectrometry (CE-MS) [46], CE-inductively coupled plasma 
(CE-ICP-MS) [47], CE-nuclear magnetic resonation (CE-NMR) [48], CE-Fourier 
transform infrared spectroscopy (CE-FTIR) [49], CE-Raman spectroscopy (CE-Raman) 
[49], and CE-X-ray [50] is capable to provide more structural elucidation. At present, 
however, only the online MS technique has sufficient detection sensitivity for structural 
identification.  
An attractive direction is to apply CE to high-throughput drug screening, for products of 
combinatorial chemistry as well as components of traditional Chinese medicine. With the 
aid of CE, binding constants and stoichiometry data can be obtained. An important 
practical aspect is that the sample may not be purified prior to CE separation. Therefore, a 
large number of samples can be screened for biological activity by a single CE run. With 
the rapid development of microfabricated devices, super high-throughput drug screening 
can become feasible on a chip-based array CE platform [51]. 
 
The method is a complementary and attractive alternative to other separation-based 
methods for evaluating binding parameters [52]. The application of CE to study receptor-
ligand interactions was first reported in 1992 [53].  From then on, CE has been widely used 
to study molecular interactions and has become a powerful tool for the determination of the 
binding parameters of various bioaffinity interactions [51].  Provided that at least one of 
the interacting compounds is soluble, can be quantitatively recovered, and when complex 
formation results in changes in electrophoretic mobility, CE is well suited for binding 
studies [52].  
The advantages often associated with CE for binding studies as compared with other 
methods are relatively short analysis time, low sample and reagent consumption, ease of 
automation, the versatility of compound  that can be studied, and high separation efficiency 
[54, 55]. The approach is much less labor intensive than equilibrium dialysis and 
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ultrafiltration where a separate analytical step, usually HPLC, is required after the initial 
separation of species.  
Errors associated with the presence of a membrane are absent and changes in affinity due 
to derivatization or immobilization and interactions with a chromatographic support are 
eliminated.  
 
Its primary disadvantage is that it cannot be used for the preparation of the analytes [56] .  
The general limitations of CE, however, also applies to affinity studies utilizing CE: 
requirements of mobility differences of charged species, lack of explicit temperature 
control, capillary wall adsorption [55].  
Different modes or formats of CE have been developed and are compared in several 
studies [52, 57] and reviews [54, 55, 58-61] [54]. 
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2.3.6 Capillary electrophoresis modes 
Methods, which are most in use to study drug-protein interactions are: affinity capillary 
electrophoresis [61], the Hummel-Dreyer, the vacancy peak, the vacancy affinity capillary 
electrophoresis [57], the zonal capillary electrophoresis [51], Frontal analysis [62] and 
frontal analysis electrophoresis capillary continual [61]. The methods can be considered as 
complementary rather then competitive techniques, because each method exhibits specific 
ranges of applicability, advantages and disadvantages [57]. Methods are applicable for 
studying interactions between drugs with HSA and AGP, lipoproteins and globulins, but it 
could not be used directly with plasma. It is required to eliminate some particles in 
suspension, which causes problems in separation system, for instance ultrafiltration [61]. 
 
2.3.6.1 Affinity capillary electrophoresis 
 
A capillary is filled with buffer containing P in varying concentrations and amount of D is 
injected. Since the equilibrium between D and P is established in the capillary, the apparent 
mobility of D depends on the binding constant and the difference between mobility of drug 
end the complex. The binding constant is calculated from the change in electrophoretic 
mobility of D. On the contrary, D can be also added on the buffer instead of P. In this case 
a small amount of P is injected as the sample. ACE has several potential advantages as 
follows: only a small amount of P and D is required, the injection sample need not be 
highly purified, and binding constants of several samples can be simultaneously 
determined [63]. 
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2.3.6.2 Vacancy affinity capillary electrophoresis 
 
VACE is a relatively new method in CE for the estimation of binding constants [57, 64].  
A capillary is filled with a running buffer containing both D and P. The concentration of 
either D or P is fixed and that of the other component is varied. The binding constants are 
estimated from the migration behavior of D as well as ACE. An advantage of the VACE is 
the fact that the absolute number of the binding sites (n) can be calculated [57]. In addition, 
VACE is particularly convenient for the estimation of binding constant of weakly soluble 
D in water because the solubility should be increased in the running buffer containing P 
[57]. 
 
2.3.6.3 Frontal analysis electrophoresis capillary continual 
 
Recently, FACCE has been developed by Gao et al. [65] as a novel CE method. The 
capillary is filled and equilibrated with buffer containing P prior the run, and the inlet of 
the capillary is immersed in the sample solution containing D and P. In this method, a 
voltage is applied for the analysis keeping the sample solution as the inlet vial. The sample 
is continuously introduced into the capillary during the analysis and the separation process 
progresses at the same time. When the mobility of D is higher than of P, the first plateau in 
the electropherogram is due to elution of free D and the second plateau is due to free D and 
drug-protein complex. A disadvantage of this method is greater sample consumption than 
the other CE methods. However, FACCE offers lower detection limits and is free from the 
reproducibility problems arising from slow binding kinetics as compared to the other CE 
methods, such as HD and the conventional FA [65]. 
 
2.3.6.4 Hummel-Dreyer 
In this type of experiment the capillary is filled with buffer containing the drug D to be 
studied at varying concentrations. When a small amount of protein P is injected a typical 
elution profile appears. The positive peak corresponds to the drug-protein complex and the 
free protein, and the negative peak emerges at the migration time of the drug. The area of 
the negative peak is directly related to the amount of drug bound to the protein. The 
number of bound drug molecules per protein molecule is fixed by the drug concentration 
in the buffer and therefore can be considered constant during elution [52]. 
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2.3.6.5 Vacancy peak 
 
In a vacancy peak experiment, the capillary is filled with buffer containing both the protein 
and the drug [52]. The concentration of one compound, for instance the protein, is fixed 
and the concentration of the other component is varied. Then a small amount of plain 
buffer is injected and typical elution profiles appear. The first negative peak arises due to a 
vacancy in the drug-protein complex and the free protein, and the second negative peak is 
due to a vacancy in the free drug concentration indicated by. The area of the second 
negative peak depends directly on the amount of free drug in the buffer. The amount of 
free drug in each buffer may be quantified from internal calibration [52, 58]. A series of 
samples (neat buffer) with increasing drug concentrations are injected. For large drug 
concentrations in the sample, the area of the trough peak changes from negative to positive. 
A simple interpolation allows the determination of the drug concentration for which the 
negative peak vanishes. From this value the amount of free drug in the buffer can be found. 
It is assumed that the protein and the complex have approximately the same mobility [58]. 
The VP method offers the possibility to check the stoichiometric model. Using the 
measured value for free drug, the known total drug concentration in the buffer, and the 
known protein concentration, the amount of drug bound by the protein can be calculated 
[57]. 
 
2.3.6.6 Capillary zonal electrophoresis 
 
In CZE the capillary is filled with buffer and sample, which contains drug and protein in 
concentrations variables in equilibrium, is injected. The separation is produced and there 
are fractions of free drug and drug-protein complex. This methodology can be applied  to 
the systems, where affinity constants are elevated and  kinetics is slow [51]. 
 
2.3.6.7 Capillary electrophoresis – frontal analysis 
 
In frontal analysis, the equilibrium between D and P is obtained in the sample vial. After 
injection of the equilibrated sample into the capillary filled with buffer electrolytes, the 
free and bound components are separated in the capillary. 
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2.3.6.8. Summary 
 
In CZE, the receptor, ligand, and complex should differ in mobility.  
In ACE, the free receptor must show a different mobility to the complex.  
In FA, there are two requirements: (i) the receptor and the complex have approximately the 
same mobility, and (ii) the mobility of the ligand differs sufficiently from the mobility of 
the complex.  
Also, in VP the receptor has an approximate mobility with the complex and HD requires 
that the ligand has a different mobility with respect to the receptor and the complex [57].  
For instance with the HD, the VP, the FA and the VACE method, both association constants 
and the number of the different binding sites can be determined, while with the ACE 
method only the binding constant can be determined and no information about the number 
of binding sites can be obtained [57]. 
 
Among these five CE modes, HD and VP are analyte consuming compared with the other 
modes but they are well suited for calculating the binding stoichiometry [66].  
 
Table 2:  Summary of CE methods and their experimental details for the estimation of 
binding constants [51, 61]. 
 
Method Sample Running solution Applicability Estimation of K 
ACE D 
P 
Buffer + P 
Buffer + D 
Fast on/off kinetics Change in mobility of D 
Change in mobility of P 
 
VACE Buffer Buffer + D + P  Change in mobility of D or 
P (vacancy peak) 
HD Buffer + D + P Buffer + P (or D) Fast on/off kinetics Peak area of vacancy peak 
corresponding to [D]f 
VP Buffer Buffer + D + P Fast on/off kinetics Peak area of vacancy peak 
corresponding to [D]f 
FA Buffer + D + P Buffer Fast on/off kinetics Plateau height 
corresponding to [D]f 
FACCE Buffer + D + P Buffer  Plateau height 
corresponding to [D]f 
CZE Buffer + D + P Buffer Fast or slow on/off 
kinetics 
Peak area of vacancy peak  
or plateau height 
corresponding to [D]f 
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In the case of strong binding, the interacting compounds and the complex have their unique 
migration mobilities, respectively. In weak binding systems, the complex dissociates 
progressively during the run, interacting compounds but not the final complex can be 
detected [67]. The distinction between strong and weak affinity interactions in CE studies 
does rest not only on a fixed value of the binding constant but also on the experimental 
setup, primarily on the separation time and buffer conditions [67].  
Generally, CZE is appropriate for the assay of strong binding systems in which the 
complex will not dissociate during the required separation time period. When a strong 
binding assay is performed, either the area or height of the peak of the interacting 
components can be used in the quantitative determination [66].  
Weak binding is typically analyzed by ACE or FA [68]. According to recent observations 
[69, 70], CZE can be also applied to study weak binding systems, in contrast to some 
former reports [54, 59]. It was found in CZE that the peak height can also be used to 
evaluate the concentration of free ligand or receptor as in FA. When only small amounts of 
samples fact, CZE and FA are identical except for a difference in the length of the analyte 
zone, which means that in CZE, the receptor and ligand can be injected immediately after 
mixing, or after certain time of incubation.  
In the case of weak binding, the use of peak height is better than the peak area for the 
quantification of analytes. 
The profiles of the interacting components depend on the degree of association of the 
receptor- ligand interaction. Besides, Joule heat, high electric field, wall effect, and 
properties of the running buffer may also influence the migration of analytes to some 
extent [66]. In studies of molecular interactions, different CE modes, equipments, or even 
differences in ligand or receptor concentrations may cause quantitative discrepancies [52, 
71, 72] 
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2.3.7 Advantages and limitations of CE-FA at drug-plasma protein 
binding studies 
 
In general, CE-FA is subject to the same advantages and limitations as other CE methods, 
but CE-FA is the method of choice because of its robustness, ease of implementation, 
capability to study multiple equilibriums, and smaller material consumption. Advantages 
include also the well-known characteristics of CE such as speed, ease of automation, 
separation power. Simplicity may be one of the main advantages of CE-FA. (Following 
equilibration of the interacting species the sample is introduced into the capillary 
containing neat buffer and voltage applied.) Separation of free ligand and analysis occur in 
one integrated step [14] and the free concentration of ligand in a particular sample can be 
determined directly [73].  
Certainly, the fact that very little effort has to be put into method development and 
optimization is a major strength of the CE-FA method [57].  
Furthermore, accordance with literature data was better than for the Hummel-Dreyer and 
vacancy peak methods [13].  
Also, CE-FA is not subject to constraints in the binding stochiometries that can be 
analyzed [57].  
CE-FA uses sample volumes 10–50 times higher than those normally used in CE. 
However, none of the interacting species has to be added to the electrophoresis buffer. This 
also avoids a large background detector response from analyte and/or ligand added to the 
electrophoresis buffer [52] which may be present in the ACE, vacancy peak, and HD 
methods as is the limitation associated with the use of indirect UV detection in terms of a 
small dynamic range [73]. 
 
Lack of sensitivity may be the main limitation to the use of CE-FA and have been pointed 
out in several studies. Therefore, capillaries with expanded light pathways have found 
some use [74-77].  
To the best of our knowledge, other more sensitive detection methods than UV have not 
been applied in CE-FA studies so far. 
In addition, limitations may apply to the mobilities of the free and complexed species 
subject to investigation.  
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Adsorption to the capillary may be a problem especially for proteins. Different types of 
coated capillaries have been applied in drug-plasma protein binding studies performed [78-
83].  
It is not possible to obtain uniform thermostating conditions across the length of a capillary 
[84], therefore lack of precise temperature control in CE-FA and other CE methods may be 
a drawback compared to conventional methods [62].  
Finally, in contrast to ACE, CE-FA may be limited to the study of pure sample and protein 
preparations [73]. 
 
The results obtained with the FA, the VP, the HD, the VACE and the ACE method clearly 
show that for drug-protein binding studies the FA method seems to be the most favorable 
one [57]. 
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2.3.8 Principles of capillary electrophoresis – frontal analysis 
 
Similar to most other CE affinity methods CE-FA has been adapted from chromatography 
[52, 57, 85]. The use of frontal analysis in chromatographic settings has been reviewed 
[85-90].  FA was first applied in a gel filtration setup by Nichol and Winzor [91] in 1964 
studying protein-protein interactions [73]. The main area of application has been drug-
plasma protein binding studies. Although CE-FA appears to have evolved from FA 
chromatography [85], it should be recognized that the theory on which FA chromatography 
is based was originally developed for electrophoresis and ultracentrifugation [91, 92]. 
Thus, there is a link from CE-FA back to early affinity studies performed using moving 
boundary electrophoresis, see [93] for a historical presentation [73]. 
The principle of FA by CE is the same as for the chromatographic approach. However, 
separation occurs due to differences in electrophoretic mobilities of free and bound ligand 
rather than due to a size-exclusion mechanism affected by a chromatographic support.  
CE-FA is based on the separation of ligand from protein and ligand-protein complex after 
the introduction of a relatively large volume (60–200 nL) of equilibrated sample mixture 
into the buffer-filled capillary. It is assumed that the protein and the complex have 
approximately the same mobility [54, 59] and  the mobility of the drug differs sufficiently 
from the mobility of the complex. Differences in mobility cause the free drug to leave the 
protein zone. Bound drug remains within the protein zone. Provided the on- and off-
kinetics is rapid, steady-state conditions and, thus, equilibrium is maintained where the 
drug and protein zones are overlapping.  
Injection of the large sample plugs give rise to the appearance of two plateau peaks 
provided the mobility of the free drug is sufficiently different from that of the protein. The 
height of the free drug plateau peak is proportional to the free drug concentration [Df] in 
the original sample and the degree of binding can be determined by aid of a calibration 
curve. Plots of the number of bound ligand molecules per molecule of protein as a function 
of the free ligand concentration yields the binding curve. Direct fitting to the experimental 
data using nonlinear regression analysis for obtaining the binding parameters is 
recommended [73]. 
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2.3.9 Requirements for using CE-FA 
 
The primary prerequisite in CE-FA is the requirement of sufficiently different migration 
times between the free and bound form of one of the species studied [52]. Otherwise 
determination of the free ligand concentrations is not feasible.  
It is suggested that CE-FA is also feasible for studying equilibrium processes irrespective 
of the magnitudes of the association and dissociation rate constants.  
Based on computer simulations Busch et al. [94] found that CE-FA is limited to systems 
where the mobility of the complex is equal to interacting receptor. Otherwise the free 
concentrations determined would be associated with an error. Experiments strongly 
indicate that low-molecular-weight drug-HSA [62], AGP [74, 75, 80, 95], and drug-
lipoprotein [96] binding fulfill these requirements. The order of magnitude of the errors 
arising from not complying with the mobility restrictions has not been assessed. It seems 
unlikely that similar size/charge ratios of complex and one of the free species can be found 
in all cases. Thus, studies addressing the influence of the mobilities of the interacting 
species and the effect of fast or slow kinetics are warranted to validate results obtained by 
CE-FA and could significantly expand the application of the method. 
Recently, it was found that plateau peaks may not be an absolute requirement in order to 
estimate binding correctly; however, the presence of plateau peaks may lead to a more 
robust method of analysis.  
For the drug-HSA interactions investigated, the extent of binding tended to be 
underestimated when small sample volumes were introduced into the capillary and plateau 
peak conditions were absent. FA is more robust because the height and thus concentration 
is not affected by changes in migration times, EOF, length of the capillary, and applied 
voltage to the same extent in a plateau peak as in a zonal peak because of the nondispersed 
zone constituting the plateau region [73]. 
Practical considerations in CE-FA include solubility in the electrophoresis buffer of 
species to be investigated, matching of the ionic strength in samples and electrophoresis 
buffer applied in order to avoid stacking phenomena, linearity of detector responses, and 
the absence of adsorption phenomena causing distortion of plateau peak shape [73]. 
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2.3.10 Application of CE-FA for the study of drug-plasma protein 
binding 
 
Knowledge of the extent of binding to plasma proteins is reflected in the large number of 
papers dealing with the determination of plasma protein binding. Also, studies using CE-
FA have focused on the most important drug-binding plasma proteins; HSA, AGP, and 
lipoproteins. CE-FA studies of drug-plasma protein binding, a few other studies have been 
performed using CE-FA only [52, 76, 97, 98]. FA in the CE format is relatively new; the 
first publication appearing in 1992 [52], thus, in many of the studies development, 
evaluation, and validation of the method have been the major theme [73]. 
 
2.3.10.1 Human serum albumin binding 
 
Kraak et al. [52] studied binding of the site I ligand warfarin to BSA. CE-FA was found to 
be the most favorable CE format when compared to Hummel-Dreyer and vacancy peak.  
Busch et al. [57] confirmed these findings in a comprehensive study including ACE and 
VACE in addition to CE-FA, Hummel-Dreyer, and vacancy peak methods.  
Østergaard et al. [62] studied the HSA binding of 12 low-molecular- weight ligands with 
widely different physicochemical properties using identical experimental conditions. Only 
two compounds failed to be analyzed with the original experimental setting. One of the 
compounds (phenylbutazone) had too small a difference in mobility from the protein and a 
distinct plateau due to the free drug was not obtained. The other compound (phenol) had a 
very weak affinity and thus the HSA concentration had to be increased to obtain reliable 
measurements of the free drug concentration [62].  
McDonnell et al. [99] studied the binding of 8  β-adrenoceptor blocking drugs.  
Jia et al.  the binding of 17 cationic and neutral drugs to HSA and AGP with only minimal 
alterations of the experimental conditions. Jia et al. used pressure-assisted CE-FA to 
shorten analysis times and improve sample throughput. In addition, application of air 
pressure was found to prevent loss of protein from sample and provide superior drug 
plateau peaks by minimizing capillary wall adsorption [100]. 
The utility and validity of binding studies performed with CE-FA have been demonstrated 
in several studies using HSA and various cationic ligands such as propranolol and 
verapamil [78, 81, 82, 99-101]. CE-FA is ideally suited for the measurement of these 
interactions because the electrophoretic mobilities of the cationic ligands and HSA 
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(negatively charged at physiological pH) are very different; moreover, the interactions 
between HSA and cationic drugs in general are relatively weak [1]. 
 
2.3.10.2. Acid glycoprotein binding 
 
AGP has also been subject to study by CE-FA. Using verapamil as a ligand Shibukawa et 
al. [78] obtained good accordance between results generated using CE-FA and 
ultrafiltration. CE-FA studies of AGP binding include work focused on estimation of the 
degree of binding of cationic drugs [78, 99, 100] and studies directed at elucidating the 
effect of AGP structure and glycation on binding [77, 80, 83]. 
 
2.3.11. The application of the short-end capillary injection   
 
This is a new, fast and simple CE-FA procedure for the study of drug-protein interactions 
at near-physiological conditions. This methodology involves the use of short-end capillary 
injection in order to reduce the analysis time. The results obtained are similar to 
conventional capillary electrophoresis and also agree with the reported bibliographic 
values. In addition, the protein binding percentages obtained with the long- and short-end 
injection schemes are in good agreement with the values found in literature. All these 
results confirm the applicability of the short-end capillary injection for the FA studies of 
drug- protein interactions with the advantage of increasing speed of analysis [102]. 
 
2.3.12 Biopartitioning micellar chromatography 
 
It was demonstrated that the retention data obtained in a chromatographic system 
constituted by a C18 reversed stationary phase and a polyoxyethylene lauryl ether micellar 
mobile phase in adequate experimental conditions are helpful in describing the biological 
behaviour of different kinds of drugs [103-114]. The usefulness of BMC in describing the 
biological behaviour of drugs could be attributed to the following features: 
The retention of a drug in this chromatographic system is mainly governed by its 
hydrophobic, electronic properties and, to a less extent, by its steric properties. These 
features of compounds also determine their passive permeability across cell membranes. In 
order to study the similarity between BMC and other well-recognised natural systems that 
mimics biomembranes, it is correlated [115] the retention data on BMC - log kBMC. 
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2.1 INSTRUMENTATION 
 
 
A Hewlett-Packard HP 3DCE capillary electrophoresis system (Agilent, AZ, USA) 
equipped with a diode array detection (DAD) system and HP 3DCE Chemstation software 
was used. 
Fused-silica capillaries (Polymicro Technologies, Phoenix, AZ, USA) of 50 µm I.D. and 
363 µm O.D. with total and effective length of 48.5 and 40 cm, respectively, were used. 
The capillary cassette temperature was set at 36.5°C and UV detection was performed at 
200, 220 and 240 nm. 
For ultrafiltration, Microcon YM-10 filters of cellulose of a molecular weight of 10000 
VCO (Millipore, Bedford, MA, USA) and a centrifuge Heraeus Biofuge Strate (Heraeus, 
Madrid, Spain) were used.  
All solutions were degassed in an ultrasonic bath (JP Selecta, Barcelona, Spain) prior to 
use. A Crison Micro pH 2000 pH meter from Crison Instruments (Barcelona, Spain) was 
employed to adjust the pH of the electrophoretic buffer. 
 
2.2 CHEMICALS AND SOLUTIONS 
 
All reagents were of analytical grade except of oxazepam. HSA and AGP were purchased 
from Sigma-Aldrich (St. Louis, U.S.A); sodium dihydrogenphosphate dihydrate was from 
Fluka Chemie GmbH (Steinheim, Germany);  
Hexobarbital, mephobarbital, butabarbital were from Sigma Chemical CO (St. Louis, MO, 
USA); phenobarbital were from Bayer (cod. 12154); Chlordiazepoxide and diazepam were 
from Guinama (Valencia, Spain); oxazepam (Adumbran
®
) was from Boeringer Ingelheim, 
S.A., (Barcelona, Spain); Barnstead E-pure deionized water (Sybron, Boston, MA, USA) 
was used to prepare solutions. 
The running buffer in all CE experiments was 67mM sodium phosphate pH 7.4 and was 
prepared by dissolving the appropriate amount of sodium dihydrogenphosphate dihydrate 
in water and adjusting the pH with NaOH 5 or 1.5M.  
500µM human serum albumin stock solutions and 40µM AGP stock solutions were daily 
prepared by dissolving the corresponding amount of protein powder with the phosphate 
buffer. Working protein solutions were obtained by dilution of HSA and AGP stock 
solutions with phosphate buffer to a final concentration of HSA 0, 25, 75, 150, 250, 350, 
475µM and of AGP 0, 5, 10, 15, 20µM.  
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Stock standard solutions of the drugs (2mM) were prepared in methanol. Working 
solutions were obtained by dilution with phosphate buffer from the corresponding stock 
solution to a final concentration of 100µM. All solutions were filtered prior to use through 
0.45 µm pore size nylon membranes (Micron Separation, Westborough, MA, USA). 
 
2.3 PROCEDURES 
 
2.3.1 Capillary conditioning 
 
New capillary was activated for 10 min flush with 1M NaOH at 60°C. Then, it was rinsed 
for 5 min with water and 15 min with phosphate buffer at 36.5°C. In order to obtain good 
peak shapes and reproducible migration times, the capillary was conditioned at the 
beginning of the day and between runs with the following sequence: (i) 2 min rinse with 
deionised water, (ii) 2 min rinse with 1M NaOH, (iii) 2 min rinse with deionised water, and 
(iv) 2 min rinse with running phosphate buffer at 1000 mbar. 
 
2.3.2 Procedure for the study of drug interactions with HSA and AGP 
by CE-FA 
Series of mixtures with increasing HSA concentration (from 0 to 475µM) and a fixed total 
concentration of drug (100µM) were prepared in duplicate by dilution of the stock 
solutions of drugs and proteins with the electrophoretic buffer.  
Mixtures containing fixed total concentration (100µM) drug and increasing AGP 
concentration (from 0 to 20µM) in phosphate buffer were also prepared in duplicate.  
The concentration protein range studied was selected according to their physiological 
concentration (HSA, 550µM; AGP, 20µM). However, the maximum HSA concentration 
studied was slightly lower than the physiological concentration in order to avoid problems 
connected with the viscosity of the solution and the Joule effect. All these solutions were 
allowed to reach equilibrium for at least 20 min before injection into the capillary system. 
Samples were injected hydrodynamically into the capillary at 50 mbar for 30 s and a 
running voltage of 15 kV was applied. 
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2.3.3 Procedure for the study of drug interactions with total plasmatic 
proteins by ultrafiltration and CE 
 
Samples were prepared in duplicate by adding 10 µl of 2mM drug solution to 200 µl of 
tested human plasma and pre-equilibrated for 30 min. The mixture was filtered through 
cellulose filters in order to prevent problems related to viscosity and capillary plugging by 
centrifugating at 12000 rpm for 40 min after having reached equilibrium. Finally, the 
ultrafiltrated fraction was injected hydrodynamically into the capillary at 50 mbar for 4 s. 
The running voltage applied was 15 kV. 
 
2.3.4 Data sources, software and data processing 
 
Binding parameters of drug to HSA were determined by using equation 5 that relates the 
free drug concentration [D]f to the total protein concentration Cp and total drug 
concentration CD [102].  
               (eq.5)                                   
 
where n1 is the number of primary binding sites and K1 its corresponding affinity constant. 
This equation assumes only one type of independent binding site in the protein molecule 
as responsible for drug binding under physiological conditions and at therapeutic drug 
concentration (10
−7
 to 10
−4
M) [102]. The parameters n1 and K1 were determined by 
adjusting the experimentally measured [D]f obtained for each CP value to eq.5 by nonlinear 
regression using MATLAB 5.3 (Matlab® Ver. 5.3.0.10183 (R11), ©The Mathworks Inc., 
Natick, MA). The determination of the protein binding percentages of drugs PB can be 
performed calculating the [D]f  value obtained for a total protein concentration of 475µM 
(eq.6). 
 
                                                                                  (eq.6)                                             
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3.1 THEORETICAL BACKGROUND 
 
 
When a certain drug solution is equilibrated with protein, the concentration of bound drug 
[D]b can be expressed as the difference between the total drug concentration CD and the 
concentration of free drug [D]f. 
 
                                                                    [D]b = CD – [D]f                                          (eq.7)                                                                                                  
 
Let to consider m types of independent binding sites per HSA molecule and drugs binding 
to any of these sites with 1:1 stoichiometry. Considering the law of mass action, the 
concentration of drug bound [D]b can be expressed as: 
 
                                                                                              (eq.8) 
 
where [D]b,i is the concentration of drug-bound at the i-site while ni and Ki are the number 
of binding sites and the affinity constant for each site, respectively. The product niCP 
represents the total concentration of binding sites of i-class. Eq. 8 is the basis of the 
traditional data treatment for determining the binding parameters of drugs to proteins from 
the nonlinear fitting of eq. 9: 
 
                                                                                                          (eq.9) 
 
where r is the concentration of bound drug molecules per HSA molecule. Substituting eq.7 
into eq. 9 and rearranging the terms it is possible to obtain the following expression that 
allows the estimation of the binding parameters by nonlinear regression assuming that one 
or two types of independent binding sites (m =1 or m = 2) in the HSA molecule are the 
main responsible of drug binding [62].  
Therefore, eq. 9 can be expressed as follows: 
 
                                                                                    (eq.10) 
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In the most general case of one type of binding site, different linearized forms of eq. 10, 
such as the Scatchard and the Klotz plots, have been developed and reviewed recently [51]. 
However, one disadvantage of eq. 10 and its linearized forms is that experimentally 
measured concentration of free drug and its derived corresponding r-values are present in 
both dependent and independent variable. Therefore, small experimental errors are 
included in both axes leading sometimes to difficulties in the interpretation of results and 
to wrong estimations of the binding parameters. One possible alternative to overcome this 
problem was proposed by McDonnell et al. [99]. They proposed an equation relating the 
experimentally measured percentage of drug bound to the protein with the total drug 
concentration. Therefore, this approach enables the determination of the binding 
parameters isolating experimental errors in the y-axis. However, these authors limited the 
application of this equation to a single class of interaction site (m = 1) assuming one 
binding site (n =1). A more general treatment can be applied from eq. 10, taking into 
account that the usual K1 and K2 values for HSA are in the range between 10
5
–10
4
 and 10
3
–
10
2
 M, respectively. This fact makes that the concentration of drugs bound at the secondary 
binding site (m= 2) under physiological conditions would only be appreciable at free drug 
concentrations over 10
–3
 M, well above the usual therapeutic levels (10
–7
–10
–4
 M) [116]. 
Therefore, the second addend in eq. 10 can be neglected in most of the cases. This leads to 
a simplification of eq. 10 giving the following expression: 
 
                                                                                                   (eq.11) 
 
Rearranging the terms of this last equation it is possible to obtain a second degree 
polynomial whose resolution provides eq. 5 that relates the free drug concentration [D]f 
with the total protein CP and drug CD concentrations. 
 
                                            
               (eq.5)                   
 
Then, a nonlinear plot of the experimentally measured [D]f   vs. CP or CD can be applied to 
the data analysis being the number of primary binding sites (n1) and its corresponding 
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constant (K1) the fitting parameters. In order to estimate drug-protein interactions at 
nearphysiological conditions, it is possible to work with two experimental setups: (A) 
series with increasing total concentration of drug (CD) and a fixed total concentration of 
protein (CP, approximately 500mM); or (B) series keeping constant CD (close to the 
therapeutical level) and increasing CP (from 0 up to 500mM). The experimental approach 
(A) would result in a great consumption of protein and thus higher costs per analysis. The 
experimental setup (B) allows reaching the physiological HSA concentration with a much 
lower cost and therefore this last setup would be preferable for high throughput 
applications and was selected to perform these studies. It is worth mentioning that reaching 
physiological protein concentration is a requirement if good estimations of drug-protein 
interactions are to be obtained since it has been reported that displacement of bound drug 
may happen due to albumin aggregation at high protein concentration [57, 117, 118]. On 
the other hand, due to the lack of sensitivity inherent to CE, total drug concentration below 
10
-4
M, leading to free drug  concentrations between 10
–4
 and 10
–6
 M, could not be used in 
this kind of studies, and therefore this total concentration value was selected for all 
experiments. Once the n1 and K1 values have been obtained using eq. 5, it is possible to use 
this equation to estimate the free drug concentration, [D]f, for a physiological HSA 
concentration (550mM). Then, the determination of the physiological drug protein binding 
percentages can be performed substituting the [D]f value obtained into eq. 6, considering a 
10
–4
 M total drug concentration.                                          
                                                                                  (eq.6)                   
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3. RESULTS AND DISCUSSION 
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3.1 EVALUATION OF PLASMATIC PROTEIN BINDING OF 
BENZODIAZEPINES AND BARBITURATES 
 
The interactions of 4 barbiturates and 3 benzodiazepines with the main plasmatic proteins 
at near physiological conditions were studied.  
For this purpose, mixtures containing a fixed drug concentration (100µM) and increasing 
concentration of HSA (from 0 to 475µM) or AGP (from 0 to 20µM) were prepared. 
Samples of benzodiazepines were injected in the short-end capillary in order to reduce 
analysis time according to the methodology described in [102], and samples containing 
barbiturates that were injected in the long-end capillary to improve the separation between 
the zones of free drug and proteins. 
The free drug concentration at each total protein concentration was determined by the 
plateau height ratio between each sample and a sample containing only drug measured in 
the electrophoreograms.  
 
 
For example, fig. 6 shows the electrophoreograms corresponding to the study of interaction 
of oxazepam with HSA and fig. 7 shows oxazepam with AGP. As it can be observed, a 
plateau corresponding to the free drug was obtained followed by the band of the protein. 
The height of the plateau decreased with increasing protein concentration reflecting the 
evolution of the complexation process.  
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Figure 6: Set of representative electrophoreograms of the binding of oxazepam to HSA. 
Injected solutions contained 20 µl with increasing protein concentration (HSA: 0, 25, 75, 
150, 250, 350 and 475µM from bottom to top). The electrophoretic buffer was 67mM 
phosphate solution at pH 7.4; temperature, 36.5°C. UV detection was performed at 240nm. 
An uncoated fused silica capillary with 48.5cm total length was used throughout. The 
injections were performed in the short-end capillary by 50mbar vacuum for 15 s and a 
running voltage -15 kV. 
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Figure 7: Set of representative electrophoreograms of the binding of oxazepam to AGP. 
Injected solutions contained 20 µl with increasing protein concentration (AGP: 0, 5, 10, 
15 and 20µM from bottom to top). The electrophoretic buffer was 67mM phosphate 
solution at pH 7.4; temperature, 36.5°C. UV detection was performed at 240 nm. An 
uncoated fused silica capillary with 4.5cm total length was used throughout. The injections 
were performed in the short-end capillary by 50 mbar vacuum for 15 s and a running 
voltage -15 kV. 
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To estimate the drug–protein affinity constant, K1 and the number of primary binding sites, 
n1, the free drug concentration [D]f obtained for each protein concentration Cp and drug 
concentration CD in duplicate were adjusted to eq. 5 and 6 respectively.  
 
 
Table 3:  Estimated K1 and n1 values. 
  
DRUG KHSA (M
-1
) nHSA PB(%) R
2
 KAGP (M
-1
) nAGP PB(%) R
2
 
         
Hexobarbital 1.1 10
3
 1 34.7 0.93 2.1 10
4
 1 14.1 0.94 
Butabarbital 1.2 10
3
 1 38.6 0.96 5.3 10
3
 1   6.6 0.86 
Mephobarbital 1.1 10
4
 1 78.9 0.99 3.7 10
4
 1  16.1 0.85 
Oxazepam 2.3 10
4
 1 95.1 0.99 7.0 10
3
 1  11.5 0.87 
Chlordiazepoxide 6.3 10
4
 1 99.8 0.99 7.0 10
4
 1  20.5 0.93 
Diazepam 7.1 10
4
 1 89.9 0.91 1.4 10
4
 2  22.7 0.98 
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Figure 8: Binding curves. Drug-AGP relationships. (a) Hexobarbital, (b) Butabarbital, (c) Oxazepam, (d) 
Chlordiazepoxide, (e) Mephobarbital, (f) Diazepam. 
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Figure 9:  Binding curves. Drug- HSA  relationships. (a) Hexobarbital, (b) Butabarbital, (c) Oxazepam, (d) 
Chlordiazepoxide, (e) Mephobarbital, (f) Diazepam. 
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To characterize the interactions of drugs with plasmatic proteins, the drug–protein binding 
percentage values to HSA (PBHSA) and to AGP (PBAGP) in physiological conditions were 
determined. 
 The free drug concentration was determined by the plateau height ratio between sample 
containing proteins and the sample containing only drug. To evaluate the interaction of 
drugs to the total plasma proteins, samples containing drug (100mM) and 200 µl of tested 
human plasma were prepared. The mixture was injected in the CE system. The free drug 
concentration was determined by the plateau height ratio between the ultrafiltrated mixture 
and the drug solutions.  
 
 
Table 4: Protein-binding values of barbiturates and benzodiazepines to HSA, AGP and 
whole plasma proteins.  
 
 
  
PBHSA (%) 
 
PBAGP (%) 
 
PBWhole plasma (%) 
 
Observed  
Bibliographic 
Observed  
Bibliographic 
 
Observed 
 
Bibliographic 
Hexobarbital 34.7  14.1  50,2±0,1 42-52 [116] 
Butabarbital 38.6    6.6  24,5±0,5 <26[119] 
Mephobarbital 78.9  16.1  60,2±0,1 59-67[120] 
Diazepam 89.9  22.7  100 98,7±0,2[121] 
Chlordiazepoxide 99.8  20.5  100 94-97[121] 
Oxazepam 95.1  11.5  100 98,8±1,8[121] 
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As an example fig. 10 shows the electrophoreograms obtained for oxazepam. 
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Figure 10: Representative electrophoreogram of the binding of oxazepam to plasmatic 
proteins . The sample solutions contained 100µM oxazepam in phosphate buffer; 100µM 
oxazepam in phosphate buffer and plasma from bottom to top. The injection was performed 
in the long-end capillary by 50 mbar vacuum for 4 s and a running voltage of 15 kV. UV 
detection was performed at 240 nm. The other experimental conditions are the same as 
before. 
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Table 5: Structure, logarithm of octanol-water partition coefficients (logP), protonation 
constants (pKa), retention data in biopartitioning micellar chromatography (log kBMC), 
molar volume (VM) and molecular weight (MW) of  the compounds studied 
 
 
Compound 
CAS 
Number 
Structure logP pKa 
log 
kBMC 
VM 
(cm
3
) 
MW 
(g/mol) 
Butabarbital 125-40-6 
N
N
H
OO
H
O
H3C
CH3
H3C
 
1.65 
7.9 
(A) 
 
 
1.36 
 
 
193 
 
 
212,2 
Chlordiazepoxide 58-25-3 
N
N
+
CH3N
O
-
Cl
H
 
2.44 
4.76 
(B) 
 
 
 
1.59 
 
 
 
231 
 
 
 
 
336,2 
Diazepam 439-14-5 
N
N
H3C
O
Cl
 
2.80 
3.3 
(B) 
 
 
 
1.65 
 
 
 
226 
 
 
 
284.74 
Hexobarbital 56-29-1 N
N
CH3
OO
H
O
H3C
 
1.49 
8.2 
(A) 
 
 
1.37 
 
 
193 
 
 
236.3 
Mephobarbital 115-38-8 N
N
CH3
OO
H
O
H3C
 
1.84 
7.8 
(A) 
 
 
 
1.48 
 
 
 
203 
 
 
 
 
 
246.3 
Oxazepam 604-75-1 
N
N
H
O
OH
Cl
 
2.24 
11.6 
(A) 
1.7 
(B) 
 
 
 
1.47 
 
 
 
202 
 
 
 
286.7 
 
Protonation constant for and acidic (A) and for a basic (B) group. 
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Table 3 shows, that all observed drugs – diazepam, oxazepam, chlordiazepoxide, 
hexobarbital, mephobarbital and butabarbital present interaction with AGP and HSA. The 
number of primary binding sites to HSA and AGP for the majority of drugs was close to 
one. In relation to affinity constants, benzodiazepines showed similar affinity to HSA and 
AGP while in case of barbiturates the affinity constants towards AGP were higher than 
towards HSA. 
 
Table 4 shows the protein-binding values of benzodiazepines and barbiturates to HSA and 
AGP. As it can be observed, the PB values of benzodiazepines to HSA were close to 100 
% while for barbiturates these values ranged between 35 and 79%. The differences 
observed between benzodiazepines and barbiturates are not so high to AGP, the values 
ranged between 7-23 %. 
The PB whole plasma protein values obtained for benzodiazepines and barbiturates and 
bibliographic data available have been included. As it can be observed, the result obtained 
agreed with the bibliographic values taken from different sources. On the other hand, the 
protein- binding values of benzodiazepines to the whole plasma proteins were 100 % and 
mainly, they bound to HSA, to a lesser extent to AGP. For barbiturates PB values to whole 
plasma proteins was 24-60 %, and also bind mainly to HSA and lesser to AGP. 
 
The following step was to evaluate the importance of some of the physicochemical 
parameters of drugs in the drug–protein interaction. Table 5 shows the structure and 
physicochemical characteristics of compounds studied. Benzodiazepines are basic drugs 
with similar hydrophobic character, the logarithm of octanol–water partition coefficient 
ranged between 2.24 and 2.80. Barbiturates are weak acids also with similar hydrophobic 
character – log P ranged between 1.49-1.84. In this table the retention data of compounds 
in biopartitioning micellar chromatography (BMC), are included. These values could be 
considered as a measure of the hydrophobicity of compounds in near physiological 
conditions [104, 122]. The molar volume and molecular weight values have been included 
in order to consider steric factors. 
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4. CONCLUSIONS 
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All observed drugs – diazepam, oxazepam, chlordiazepoxide, hexobarbital, mephobarbital 
and butabarbital present interaction with AGP and HSA. The number of primary binding 
sites to HSA and AGP for the majority of drugs was close to one. In relation to affinity 
constants, benzodiazepines showed similar affinity to HSA and AGP while in case of 
barbiturates  the affinity constants towards AGP were higher than towards HSA. 
 
The analysis of the results obtained for PBHSA, PBAGP, PBwhole plasma revealed that the 
hydrophobic character of compounds expressed as logP and/or log kBMC is the most 
important factor to describe drug–protein interactions. That is why benzodiazepines bind to 
HSA with larger extent than barbiturates. The rest of variables were less important or 
unreliable with the present data. Fig. 11 shows the variation of PBHSA, PBAGP, PB whole plasma 
protein with log kBMC of compounds. As it can be observed, the PB of basic drugs to 
proteins increased with increasing log kBMC, which is the hydrophobicity of compounds. 
 
 
 
 
 
Figure 11: Variation of PBHSA, PBAGP, PB whole plasma protein with log kBMC of compounds. 
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ABSTRACT 
 
An important topic in the drug discovery and development process is the role of drug 
binding to plasma proteins. In this diploma thesis the characterization of the interaction 
between benzodiazepines and barbiturates towards human serum albumin and α-1-acid 
glycoprotein under physiological conditions by capillary electrophoresis-frontal analysis is 
presented.  Furthermore, the binding of these drugs to all plasma proteins is evaluated by 
using ultrafiltration and capillary electrophoresis. The results indicate that the hydrophobic 
character of compounds seems to be the key factor on the interaction between these drugs 
towards proteins. In fact, hydrophobic basic drugs (benzodiazepines) bind in great 
extension to HSA, while less hydrophobic acid drugs (barbiturates) present lower 
interactions with proteins and bind especially to AGP. 
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ABSTRAKT 
 
Důležitým směrem výzkumu při vývoji nových léčiv je jejich vazba na plasmatické 
proteiny. Tato diplomová práce charakterizuje interakce vybraných barbiturátů a 
benzodiazepinů s lidským sérovým albuminem a alfa glykoproteinem za fyziologických 
podmínek metodou kapilární elektroforézou – frontální analýzou. Navíc je sledována 
vazba vybraných barbiturátů a benzodiazepinů celkově ke všem proteinům plasmy  
kapilární elektroforézou po provedení ultrafiltrace. Výsledky ukazují, že rozhodující faktor 
pro vazbu na sérové proteiny je hydrofóbní charakter sloučenin.  
 
 
